Caredx (CDNA) Stock
Diagnostic company for organ transplant monitoring. Here's the price, business snapshot, and what's worth knowing about Caredx in July 2026.
CareDx, Inc. (CDNA) specialises in diagnostic tests and monitoring solutions for organ transplant patients. Its portfolio includes non‑invasive assays such as donor‑derived cell‑free DNA (AlloSure) and gene‑expression tests (AlloMap) designed to detect rejection and guide post‑transplant care. The company’s model combines laboratory services, test kits and licensing, which can generate recurring revenue from ongoing patient surveillance. Key drivers include rising transplant volumes globally, greater clinician adoption of non‑invasive monitoring, and geographic expansion. Investors should weigh these opportunities against risks: reimbursement uncertainty, competitive assays, regulatory scrutiny and the need for continued clinical evidence. With a market capitalisation near $808.5m, CareDx sits in the smaller‑cap diagnostic space where growth potential comes with higher volatility. This summary is educational only and not personalised financial advice — prospective investors should review the company’s latest filings and consider their own suitability and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying CareDx's stock, forecasting a potential decrease to $22.67.
Financial Health
CareDx Inc is generating decent revenue and cash flow, but profitability remains a concern.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CDNA
Renal Therapy Stocks (Biopharma & Research) In Focus
Vertex Pharmaceuticals recently achieved significant late-stage trial success for its experimental kidney disease drug, paving the way for accelerated regulatory approval. This breakthrough spotlights a broader investment opportunity in biopharmaceutical companies and medical researchers developing innovative treatments for chronic renal conditions.
Published: 10 March 2026
Explore BasketActivist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: 11 August 2025
Explore BasketThe Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: 27 July 2025
Explore BasketLiquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: 17 June 2025
Explore BasketPersonalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue potential
Monitoring tests can generate repeat business as patients require long‑term surveillance, offering predictable revenue per patient — though reimbursement and volumes can vary.
Innovation in monitoring
Proprietary tests like donor‑derived cell‑free DNA and gene‑expression panels aim to reduce invasive biopsies and improve care, but continued clinical validation is important.
Market expansion path
Global transplant growth and partnerships could open new markets, yet regulatory differences and payer coverage can affect uptake and timing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
